JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

MDT

91.7

-0.83%↓

ELV.US

293.36

+1.69%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

MDT

91.7

-0.83%↓

ELV.US

293.36

+1.69%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

MDT

91.7

-0.83%↓

ELV.US

293.36

+1.69%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

MDT

91.7

-0.83%↓

ELV.US

293.36

+1.69%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

MDT

91.7

-0.83%↓

ELV.US

293.36

+1.69%↑

Search

Bio-Techne Corp

Ouvert

SecteurSoins de santé

57.77 -0.21

Résumé

Variation du prix de l'action

24h

Actuel

Min

57.11

Max

58.25

Chiffres clés

By Trading Economics

Revenu

-12M

23M

Ventes

19M

316M

P/E

Moyenne du Secteur

70.542

40.048

Rendement du dividende

0.54

Marge bénéficiaire

7.144

Employés

3,100

EBITDA

-7.1M

68M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+13.29% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.54%

2.45%

Prochains Résultats

6 août 2025

Date du Prochain Dividende

29 août 2025

Date du Prochain Détachement de Dividende

18 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.4B

9.2B

Ouverture précédente

57.98

Clôture précédente

57.77

Sentiment de l'Actualité

By Acuity

67%

33%

341 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Bio-Techne Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 juil. 2025, 23:57 UTC

Acquisitions, Fusions, Rachats

EQT: To Spend Y407.82B for Tender Offer

29 juil. 2025, 23:56 UTC

Acquisitions, Fusions, Rachats

EQT: Tender Offer Price Is Y5,700 a Share

29 juil. 2025, 23:54 UTC

Acquisitions, Fusions, Rachats

EQT To Start Tender Offer for Fujitec

29 juil. 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 juil. 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 juil. 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 juil. 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 juil. 2025, 22:44 UTC

Acquisitions, Fusions, Rachats

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 juil. 2025, 22:41 UTC

Acquisitions, Fusions, Rachats

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 juil. 2025, 22:41 UTC

Acquisitions, Fusions, Rachats

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 juil. 2025, 22:35 UTC

Résultats

IGO Maintains Nova Life of Mine Production Guidance

29 juil. 2025, 22:35 UTC

Résultats

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 juil. 2025, 22:35 UTC

Résultats

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 juil. 2025, 22:34 UTC

Résultats

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 juil. 2025, 22:34 UTC

Résultats

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 juil. 2025, 22:34 UTC

Market Talk
Résultats

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 juil. 2025, 22:33 UTC

Résultats

IGO Had A$279.7 Million of Cash at End-June

29 juil. 2025, 22:33 UTC

Résultats

IGO 4Q Underlying Free Cash A$2.4 Million

29 juil. 2025, 22:33 UTC

Résultats

IGO FY Sales Revenue A$512.5 Million

29 juil. 2025, 22:33 UTC

Résultats

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 juil. 2025, 22:32 UTC

Résultats

IGO FY Nickel Production 17,173 Tons

29 juil. 2025, 22:32 UTC

Résultats

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 juil. 2025, 22:32 UTC

Résultats

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 juil. 2025, 22:31 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

29 juil. 2025, 22:31 UTC

Market Talk
Résultats

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 juil. 2025, 22:31 UTC

Résultats

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 juil. 2025, 22:31 UTC

Résultats

IGO FY Spodumene Production 1.48 Million Tons

29 juil. 2025, 22:30 UTC

Résultats

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 juil. 2025, 22:30 UTC

Résultats

IGO 4Q Underlying Ebitda A$62 Million

29 juil. 2025, 22:22 UTC

Résultats

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparaison

Variation de prix

Bio-Techne Corp prévision

Objectif de Prix

By TipRanks

13.29% hausse

Prévisions sur 12 Mois

Moyen 66.33 USD  13.29%

Haut 75 USD

Bas 59 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

9

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

49.67 / 50.24Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

341 / 375Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.